Hofseth Biocare ASA: HBC discovers new drug candidate for asthma and transfers it to HBC Immunology Inc.
July 02, 2024 03:00 ET
|
Hofseth Biocare ASA
Ålesund, 02.07.24, Hofseth BioCare ASA ("HBC" or the "Company"), a global leader in marine lipid and peptide research, today announces the decision to transfer its eosinophil-targeting drug candidate...
Hofseth Biocare ASA: AGREES CHINA DISTRIBUTION PARTNERSHIP WITH SHANGHAI-BASED LITHY
June 11, 2024 03:00 ET
|
Hofseth Biocare ASA
Hofseth BioCare ASA (HBC) is delighted to announce the appointment of Lithy One-Health Group Technology Co. Ltd (Lithy) as an additional distributor in China. Shanghai-based Lithy has entered into...
Hofseth Biocare ASA: FIRST QUARTER 2024 FINANCIAL REPORT
May 16, 2024 02:00 ET
|
Hofseth Biocare ASA
The first quarter of 2024 continued on the positive trend for HBC. Sales revenues came in at NOK 52m vs NOK 44m last year, a growth of 17 % YoY. The underlying growth we are seeing is coming from both...
Hofseth Biocare ASA: Annual General Meeting completed
May 10, 2024 08:30 ET
|
Hofseth Biocare ASA
Hofseth BioCare ASA held its Annual General Meeting on 10 May 2024. 270,174,810 shares, amounting to 68.38 per cent of the share capital, were represent in the meeting or by proxy. All proposals were...
Hofseth Biocare ASA: NOTICE OF ANNUAL GENERAL MEETING 2024
April 19, 2024 07:00 ET
|
Hofseth Biocare ASA
The Annual General Meeting of Hofseth BioCare ASA for 2024 will be held at the company's premises at Keiser Wilhelms gate 24, 6003 Ålesund, on 10 May 2024 at 13:00 CET. The notice of the Annual...
Hofseth Biocare ASA: HBC ANNUAL REPORT 2023
April 19, 2024 02:00 ET
|
Hofseth Biocare ASA
The Board of Directors of Hofseth BioCare ASA ("HBC") has approved the financial statements for 2023 and the Company has today published the Annual Report and Sustainability Report for 2023. Please...
Hofseth Biocare ASA: DISCLOSURE OF LARGE SHAREHOLDING
April 05, 2024 12:08 ET
|
Hofseth Biocare ASA
Today, 5 April 2024, funds managed by Bonafide (Bonafide Global Fish Fund, Bonafide Best Catches I, HBC I, and HBC II) have purchased approx. 7.1 million shares in Hofseth BioCare ASA (“HBC”),...
Hofseth Biocare ASA: UPDATED COMPANY PRESENTATION
March 21, 2024 05:40 ET
|
Hofseth Biocare ASA
Please find the HBC Company Presentation attached. For further information, please contact: James Berger, Chief Commercial Officer of Hofseth BioCare ASA Phone: +41 79 950 10 34 E-mail:...
Hofseth Biocare ASA: CHAIR KRISTIN FJELLBY GRUNG STEPS DOWN
March 14, 2024 07:12 ET
|
Hofseth Biocare ASA
Kristin Fjellby Grung, Chair of the Board of Hofseth BioCare ASA, has informed the Board of Directors that she will resign from the position on 31 March 2024, as she will assume a position as judge in...
Hofseth Biocare ASA: FOURTH QUARTER 2023 AND FULL YEAR FINANCIAL REPORT
February 09, 2024 02:00 ET
|
Hofseth Biocare ASA
HBC had gross operating revenues of NOK 47.4m (33.6m) in the fourth quarter and NOK 218.5m (120.4m) for the full year. Adjusted for the sale of assets in the second quarter, operating revenues were...